TG Therapeutics Inc (TGTX)
Cash conversion cycle
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 209.13 | 106.22 | — | — | — |
| Days of sales outstanding (DSO) | days | 145.35 | 84.37 | — | 75.79 | — |
| Number of days of payables | days | — | — | — | — | — |
| Cash conversion cycle | days | 354.49 | 190.59 | 0.00 | 75.79 | 0.00 |
December 31, 2024 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 209.13 + 145.35 – —
= 354.49
TG Therapeutics Inc's cash conversion cycle has shown fluctuations over the years.
On December 31, 2020, the company had a cash conversion cycle of 0.00 days, indicating that the company was able to convert its inventory and accounts receivable into cash almost instantly.
By December 31, 2021, the cash conversion cycle increased significantly to 75.79 days. This suggests that the company took longer to convert its products and services into cash during this period.
In the following year, on December 31, 2022, the cash conversion cycle returned to 0.00 days, which was a positive sign as the company was able to efficiently manage its working capital and convert it into cash quickly.
However, by December 31, 2023, the cash conversion cycle increased sharply to 190.59 days, indicating a potential issue with the company's liquidity or inefficient management of working capital during this period.
By the most recent period of December 31, 2024, the cash conversion cycle further increased to 354.49 days, signifying a significant delay in converting inventory and accounts receivable into cash, which may raise concerns about the company's overall financial health and operational efficiency.
Overall, the trend in TG Therapeutics Inc's cash conversion cycle shows fluctuations over the years, indicating periods of efficient cash conversion as well as potential challenges in working capital management and liquidity.
Peer comparison
Dec 31, 2024